See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

STAT™ Medical Devices

Roger Huckleberry

STAT™ Medical Devices

Multi-Talented Diabetes Educator Is a Joy to the World

Joy Pape, RN, BSN, CDE, WOCN, CFCN

Multi-Talented Diabetes Educator Is a Joy to the World

ReliOn at Wal-Mart

Bob Guest

ReliOn at Wal-Mart

Invokana

Updated 45 weeks ago
Assessing a New Class of Type 2 Drugs
Jan 30, 2014 | 
The name alone is a mouthful. Sodium-glucose cotransporter-2 inhibitors are one of the newest class of drugs meant to treat type 2 diabetes, but you can be forgiven if the name doesn't trip lightly off your tongue. The conspicuously vowel-free abbreviation--SGLT2--isn't much better.
First-World Type 2 Drug Market to Reach $47 Billion by 2022
Oct 18, 2013 | 
A Massachusetts-based research firm concludes that the first-world market for type 2 drugs and treatments will increase from $27 billion in sales in 2012 to $47 billion in 2022.
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

STAT™ Medical Devices

Roger Huckleberry

STAT™ Medical Devices

Multi-Talented Diabetes Educator Is a Joy to the World

Joy Pape, RN, BSN, CDE, WOCN, CFCN

Multi-Talented Diabetes Educator Is a Joy to the World

ReliOn at Wal-Mart

Bob Guest

ReliOn at Wal-Mart

FDA Approves Invokana, a New Type 2 Drug
Jun 27, 2013 | 
A new, first-in-its-class drug for type 2 diabetes has just been approved by the Food and Drug Administration. Invokana works by blocking re-absorption of glucose by the kidneys and stimulating urination, which removes glucose from the bloodstream.

Fatal error: Call to a member function getUrl() on a non-object in /home/diabetes/public_html/browse.php on line 54